The Food and Drug Administration (FDA) granted full approval of Moderna’s COVID-19 jab, Spikevax, in children 6 months through 11 years of age considered “increased risk” for COVID-19.
“Today we announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for Spikevax®, our COVID-19 vaccine, in children 6 months through 11 years of age who are at increased risk for COVID-19 disease,” Moderna stated.
“Our COVID-19 vaccine, mRNA-1273, was previously available for pediatric populations under Emergency Use Authorization,” it added.
Today we announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for Spikevax®, our COVID-19 vaccine, in children 6 months through 11 years of age who are at increased risk for COVID-19 disease.
Trending: Ukrainian air force officer accused of leaking location of NATO F-16 jets to Russia
Join the conversation!
Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!